Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Active not recruiting × regorafenib × Clear all

Phase

Phase 2 10 Phase 3 4 Phase 1/2 3 Phase 2/3 1 Phase 1 1

Status

Completed 26 Terminated 5 Unknown 4 Withdrawn 1 Suspended 1 Recruiting 1 Not yet recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma, Ewing 1

Interventions

pembrolizumab 83 Cyclophosphamide 74 Nivolumab 53 fludarabine 46 Specimen Handling 39 Carboplatin 37 Magnetic Resonance Spectroscopy 36 Biopsy 32 fludarabine phosphate 29 Radiotherapy 26 Paclitaxel 26 Gemcitabine 25 Cisplatin 25 atezolizumab 24 venetoclax 22 Radiosurgery 21 Radiation 19 Ipilimumab 19 Dexamethasone 19 durvalumab 18 Bevacizumab 18 Rituximab 17 Lenalidomide 17 Temozolomide 16 Decitabine 16 Pemetrexed 15 Injections 15 Oxaliplatin 14 Fluorouracil 14 Docetaxel 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05830084 2026-01-06

REGO-INTER-EWI

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1 Active not recruiting

Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon ⚡